Insider Buying: Cooper Companies (NASDAQ:COO) Director Buys 1,000 Shares of Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Maria Rivas purchased 1,000 shares of the company’s stock in a transaction dated Thursday, December 18th. The stock was purchased at an average price of $82.13 per share, with a total value of $82,130.00. Following the completion of the purchase, the director directly owned 11,141 shares in the company, valued at $915,010.33. The trade was a 9.86% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Cooper Companies Price Performance

COO stock traded up $0.29 during midday trading on Friday, reaching $82.75. 3,561,438 shares of the stock were exchanged, compared to its average volume of 2,478,541. The stock has a market capitalization of $16.22 billion, a PE ratio of 44.02, a P/E/G ratio of 2.35 and a beta of 1.05. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13. The company has a fifty day moving average price of $74.41 and a 200 day moving average price of $71.89. The Cooper Companies, Inc. has a 52 week low of $61.78 and a 52 week high of $100.24.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.04. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The firm had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the prior year, the company posted $1.04 EPS. The company’s revenue was up 4.6% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. As a group, analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies announced that its Board of Directors has authorized a share buyback program on Wednesday, September 17th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical device company to purchase up to 15.4% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its stock is undervalued.

Hedge Funds Weigh In On Cooper Companies

Large investors have recently bought and sold shares of the stock. Buckhead Capital Management LLC raised its stake in Cooper Companies by 14.3% during the 3rd quarter. Buckhead Capital Management LLC now owns 58,930 shares of the medical device company’s stock valued at $4,040,000 after buying an additional 7,368 shares during the last quarter. Amundi increased its position in shares of Cooper Companies by 35.5% during the 2nd quarter. Amundi now owns 1,331,480 shares of the medical device company’s stock valued at $97,225,000 after purchasing an additional 348,652 shares during the last quarter. Janney Montgomery Scott LLC boosted its holdings in shares of Cooper Companies by 5.1% in the second quarter. Janney Montgomery Scott LLC now owns 97,394 shares of the medical device company’s stock worth $6,931,000 after buying an additional 4,761 shares during the last quarter. United Services Automobile Association bought a new stake in Cooper Companies during the first quarter valued at approximately $414,000. Finally, Westwood Holdings Group Inc. increased its holdings in Cooper Companies by 23.4% during the second quarter. Westwood Holdings Group Inc. now owns 311,745 shares of the medical device company’s stock valued at $22,184,000 after buying an additional 59,190 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Needham & Company LLC reissued a “buy” rating and issued a $100.00 price target (up from $94.00) on shares of Cooper Companies in a research note on Friday, December 5th. Weiss Ratings reissued a “sell (d+)” rating on shares of Cooper Companies in a research note on Monday. Morgan Stanley upped their price objective on shares of Cooper Companies from $76.00 to $83.00 and gave the company an “equal weight” rating in a report on Monday, December 8th. Robert W. Baird raised their target price on Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a research note on Friday, December 5th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $94.00 price target (up from $83.00) on shares of Cooper Companies in a research note on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Cooper Companies currently has a consensus rating of “Moderate Buy” and an average price target of $90.15.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.